Antifungal pharmacotherapy for invasive mould infections

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 2, 2003, Pages 147-164

  Gallagher, Jason C ^a   Dodds Ashley, Elizabeth S ^a,b   Drew, Richard H ^a,c   Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CAMPBELL UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphotericin B; Antifungal therapy; Aspergillosis; Caspofungin; Fungal infection; Mould infection; Voriconazole

Indexed keywords

ABLECET; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ATORVASTATIN; BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CASPOFUNGIN; DOFETILIDE; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MICAFUNGIN; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; PROTEINASE INHIBITOR; QUINIDINE; RAPAMYCIN; RAVUCONAZOLE; RIFAMPICIN; SIMVASTATIN; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DERMATOMYCOSIS; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; EARLY DIAGNOSIS; FUSARIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFECTION COMPLICATION; LUNG INFECTION; MORBIDITY; MORTALITY; MOULD; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PREVALENCE; REVIEW; SCEDOSPORIUM APIOSPERMUM; TABLET FORMULATION;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; LUNG DISEASES, FUNGAL; MITOSPORIC FUNGI; MYCOSES;

EID: 0037329367     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.2.147     Document Type: Review

References (163)

1. MARR KA, CARTER RA, CRIPPA F, WALD A, COREY L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. (2002) 34(7):909-917.
2. SINGH N: Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin. Infect. Dis. (2001) 33(10):1692-1696.
3. BOUTATI EI. ANAISSIE EJ: Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood (1997) 90(3):999-1008.
4. CHAKRABARTI A, DAS A, SHARMA A et al.: Ten years' experience in zygomycosis at a tertiary care centre in India. J. Infect. (2001) 42(4):261-266.
5. EUCKER J, SEZER O, GRAF B, POSSINGER K: Mucormycoses. Mycoses (2001) 44(7):253-260.
6. OLIVEIRA JS, KERBAUY FR, COLOMBO AL et al.: Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole. Braz. J. Med. Biol. Res. (2002) 35(7):789-798.
7. NAYAK DR, BALAKRISHNAN R, NAINANI S, SIDDIQUE S: Paecilomyces fungus infection of the paranasal sinuses. Int. J. Pediatr. Otorhinolaryngol. (2000) 52(2):183-187
8. MARQUES SA, ROBLES AM, TORTORANO AM, TUCULET MA, NEGRONI R, MENDES RP: Mycoses associated with AIDS in the Third World. Med. Mycol. (2000) 38:S269-S279.
9. WALD A, LEISENRING W, VAN BURIK JA, BOWDEN RA: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. (1997) 175(6):1459-1466.
10. HUGHES WT, ARMSTRONG D, BODEY GP et al.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. (2002) 34(6):730-751.
11. KAPLAN JE, MASUR H, HOLMES KK et al.: An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. Clin. Infect. Dis. (2000) 30:S15-S28.
12. GROSSI P, FARINA C, FIOCCHI R, DALLA GD: Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Transplantation (2000) 70(1):112-116.
13. LIN SJ, SCHRANZ J, TEUTSCH SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. (2001) 32(3):358-366.
14. ALANGADEN GJ, WAHIDUZZAMAN M, CHANDRASEKAR PH: Aspergillosis: the most common community-acquired pneumonia with Gram-negative bacilli as copathogens in stem cell transplant. recipients with graft-versus-host disease. Clin. Infect. Dis. (2002) 35(6):659-664.
15. STEVENS DA, KAN VL, JUDSON MA et al.: Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):696-709.
16. ANAISSIE EJ, COSTA SF: Nosocomial aspergillosis is waterborne. Clin. Infect. Dis. (2001) 33(9):1546-1548.
17. ANAISSIE EJ, STRATTON SL, DIGNANI MC et al.: Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin. Infect. Dis. (2002) 34(6):780-789.
18. PINKER S: ORs closed after Aspergillus discovered at Royal Vic. Can. Med. Assoc. J. (2001) 164(9):1333.
19. KONTOYIANNIS DP, SUMOZA D, TARRAND J, BODEY GP, STOREY R, RAAD II: Significance of aspergillemia in patients with cancer: a 10-year study. Clin. Infect. Dis. (2000) 31(1):188-189.
20. BUCHHEIDT D, BAUST C, SKLADNY H, BALDUS M, BRAUNINGER S, HEHLMANN R: Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br. J. Haematol. (2002) 116(4):803-811.
21. KAMI M, FUKUI T, OGAWA S et al.: Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin. Infect. Dis. (2001) 33(9):1504-1512.
22. MAERTENS J, VERHAEGEN J, DEMUYNCK H et al.: Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J. Clin. Microbiol. (1999) 37(10):3223-3228.
23. HERBRECHT R, LETSCHER-BRU V, OPREA C et al.:: Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. (2002) 20(7):1898-1906.
24. ELLIS D: Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. (2002) 49:S7-S10.
25. DERAY G: Amphotericin B nephrotoxicity. J. Antimicrob. Chemother. (2002) 49:S37-S41.
26. WINGARD JR, KUBILIS P, LEE L et al.: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. (1999) 29(6):1402-1407.
27. DUPONT B: Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. (2002) 49:S31-S36.
28. BOWDEN R, CHANDRASEKAR P, WHITE MH et al.: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. (2002) 35(4):359-366.
29. DREW RH, PALMER SM, DAVIS R, PERFECT JR: Invasive fungal infections (IFIs) in lung transplant recipients (LTR) receiving prophylactic aerosolized amphotericin B (aAmB) formulations. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002) M-1236.
30. PALMER SM, DREW RH, WHITEHOUSE JD et al.: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation (2001) 72(3):545-548.
31. RUFFNI E, BALDI S, LIBERTUCCI D et al.: Aerosolized liposomal amphotericin B: a novel and effective treatment for Aspergillus infections in lung transplant recipients. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M-1237.
32. SCHWARTZ S, BEHRE G, HEINEMANN V et al.: Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood (1999) 93(11):3654-3661.
33. REICHENSPURNER H, GAMBERG P, NITSCHKE M et al.: Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplantation Proc. (1997) 29(1-2):627-628.
34. HERTENSTEIN B, KERN WV, SCHMEISER T et al.: Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann. Hematol. (1994) 68(1):21-26.
35. MYERS SE, DEVINE SM, TOPPER RL et al.: A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk. Lymphoma. (1992) 8(3):229-233.
36. VELTRI A, ANSELMETTI GC, BARTOLI G et al.: Percutaneous treatment with amphotericin B of mycotic lung lesions from invasive aspergillosis: results in 10 immunocompromised patients. Eur. Radiol. (2000) 10(12):1939-1944.
37. MERCK AND CO.: Cancidas (caspofungin acetate) package insert. Whitehouse Station, NJ. (2001).
38. MAERTENS J, RAAD I, PETRIKKOS G et al.: Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractor (R) or intolerant (I) to other antifungal agents: analysis of 90 patients. Proceedings of the 42nd Interscience Conference an Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002):M-868.
39. DENNING DW, RIBAUD P, MILPIED N et al.: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. (2002) 34(5):563-571.
40. HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. (2002) 347(6):408-415.
41. KONTOYIANNIS DP, BODEY GP: Invasive aspergillosis in 2002: an update. Eur. J. Clin. Microbiol. Infect. Dis. (2002) 21(3):161-172.
42. GEORGOPAPADAKOU NH: Update on antifungals targeted to the cell wall: focus on β-1,3-glucan synthase inhibitors. Expert Opin. Investig. Drugs. (2001) 10(2):269-280.
43. OSHAUGHNESSY EM, PETER J, WALSH TJ: In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002)M-856.
44. OSTROSKY-ZEICHNER L, MATAR M, PAETZNICK VL, RODRIGUEZ JR, CHEN E, REX JH: In vitro synergy testing of anidulafungin (AFG) and micafungin (MFG) in combination with amphotericin B (AMB) against Aspergillus spp. and Fusarium spp. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002) M-1816.
45. MARICHAL P, VANDEN BOSSCHE H: Mechanisms of resistance to azole antifungals. Acta. Biochim. Pol. (1995) 42(4):509-516.
46. JANSSEN PHARMACEUTICAL PRODUCTS: Sporanox (itraconazole) package insert. Raritan, N. J. (2002).
47. DENNING DW, LEE JY, HOSTETLER JS et al.: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. (1994) 97(2):135-144.
48. CAILLOT D, BASSARIS H, MCGEER A et al: Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin. Infect. Dis. (2001) 33(8):e83-e90.
49. SLAIN D, ROGERS PD, CLEARY JD, CHAPMAN SW: Intravenous itraconazole. Ann. Pharmacother. (2001) 35(6):720-729.
50. RARONE JA, MOSKOVITZ BL, GUARNIERI J et al.: Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother. (1998) 42(7):1862-1865.
51. PFIZER INC.: Vfend (voriconazole) package insert. New York, NY. (2002).
52. ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36(10):2950-2956.
53. KIRKPATRICK WR, PEREA S, COCO BJ, PATTERSON TF: Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J. Antimicrob. Chemother. (2002) 49(2):353-37.
54. HAYETTE MP, AMADORE A, SEIDEL N et al.: Comparative in vitro activity of amphotericine B, itraconazole, voriconazole and posaconazole against Aspergillus fumigatus. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001).
55. STEVENS DA: Combination immunotherapy and antifungal chemotherapy. Clin. Infect. Dis. (1998) 26(6):1266-1269.
56. CASADEVALL A, PIROFSKI LA: Adjunctive immune therapy for fungal infections. Clin. Infect. Dis. (2001) 33(7):1048-1056.
57. TAMM M, MALOUF M, GLANVILLE A: Pulmonary scedosporium infection following lung transplantation. Transpl. Infect. Dis. (2001) 3(4):189-194.
58. MELETIADIS J, MEIS JF, MOUTON JW et al.: In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother. (2002) 46(1):62-68.
59. REVANKAR SG, PATTERSON JE, SUTTON DA, PULLEN R, RINALDI MG: Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin. Infect. Dis. (2002) 34(4):467-476.
60. TIRADO-MIRANDA R, SOLERA-SANTOS J, BRASERO JC, HARO-ESTARRIOL M, CASCALES-SANCHEZ P, IGUALADA JB: Septic arthritis due to Scedosporium apiospermum: case report and review. J. Infect. (2001) 43(3):210-212.
61. NESKY MA, MCDOUGAL EC, PEACOCK JE Jr: Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin. Infect. Dis. (2000) 31(3):673-677.
62. NONAKA D, YFANTIS H, SOUTHALL P, SUN CC: Pseudallescheriasis as an aggressive opportunistic infection in a bone marrow transplant recipient. Arch. Pathol. Lab. Med. (2002) 126(2):207-209.
63. SIMARRO E, MARIN F, MORALES A, SANZ E, PEREZ J, RUIZ J: Fungemia due to Scedosporium prolificans: a description of two cases with fatal outcome. Clin. Microbiol. Infect. (2001) 7(11):645-647.
64. MAERTENS J, LAGROU K, DEWEERDT H et al.: Disseminated infection by Scedosporium prolificans: an emerging fatality among haematology patients. Case report and review. Ann. Hematol. (2000) 79(6):340-344.
65. AL REFAI M, DUHAMEL C, LE ROCHAIS JP, ICARD P: Lung scedosporiosis: a differential diagnosis of aspergillosis. Eur. J. Cardiothorac. Surg. (2002) 21(5):938-939.
66. LOPEZ FA, CROWLEY RS, WASTILA L, VALANTINE HA, REMINGTON JS: Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient: a case of mistaken identity. J. Heart Lung Transplant. (1998) 17(3):321-324.
67. RAJ R, FROST AE: Scedosporium apiospermum fungemia in a lung transplant recipient. Chest (2002) 121(5):1714-1716.
68. DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. (1997) 41(8):1835-1836.
69. POZA G, MONTOYA J, REDONDO C et al.: Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin. Infect. Dis. (2000) 30(6):981-982.
70. MUNOZ P, MARIN M, TORNERO P, MARTIN RP, RODRIGUEZ-CREIXEMS M, BOUZA E: Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin. Infect. Dis. (2000) 31(6):1499-1501.
71. JABADO N, CASANOVA JL, HADDAD E et al.: Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin. Infect. Dis. (1998) 27(6):1437-1441.
72. MELLINGHOFF IK, WINSTON DJ, MUKWAYA G, SCHILLER GJ: Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin. Infect. Dis. (2002) 34(12):1648-1650.
73. AFELTRA J, DANNAOUI E, MEIS JFM, RODRIGUEZ-TUDELA JL, VERWEIJ PE: In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob. Agents Chemother. (2002) 46(10):3323-3326.
74. GUARRO J, NUCCI M, AKITI T, GENE J, BARREIRO MD, GONCALVES RT: Fungemia due to Fusarium sacchari in an immunosuppressed patient. J. Clin. Microbiol. (2000) 38(1):419-421.
75. MUSA MO, AL EISA A, HALIM M et al.: The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br. J. Haematol. (2000) 108(3):544-548.
76. PEREIRO M Jr, ABALDE MT, ZULAICA A et al.: Chronic infection due to Fusarium oxysporum mimicking lupus vulgaris: case report and review of cutaneous involvement in fusariosis. Acta. Derm. Venereol. (2001) 81(1):51-53.
77. TIRIBELLI M, ZAJA F, FILI C et al.: Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia. Eur. J. Haematol. (2002) 68(5):314-317.
78. NUCCI M, ANAISSIE E: Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin. Infect. Dis. (2002) 35(8):909-920.
79. SAMPATHKUMAR P, PAYA CV: Fusarium infection after solid-organ transplantation. Clin. Infect. Dis. (2001) 32(8):1237-1240.
80. GUARRO J, PUJOL I, MAYAYO E: In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob. Agents Chemother. (1999) 43(5):1256-1257.
81. GOLDBLUM D, FRUEH BE, ZIMMERLI S, BOHNKE M: Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex. Cornea (2000) 19(6):853-856.
82. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. (2001) 45(1):327-330.
83. PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. (1998) 30(4):251-255.
84. ESPINEL-INGROFF A: In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J. Clin. Microbiol. (2001) 39(3):954-958.
85. CLANCY CJ, NGUYEN MH: In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. (1998) 17(8):573-575.
86. REIS A, SUNDMACHER R, TINTELNOT K, AGOSTINI H, JENSEN HE, ALTHAUS C: Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br. J. Ophthalmol. (2000) 84(8):932-933.
87. LOZANO-CHIU M, ARIKAN S, PAETZNICK VL, ANAISSIE EJ, LOEBENBERG D, REX JH: Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. (1999) 43(3):589-591.
88. HERBRECHT R, LETSCHER-BRU V, BOWDEN RA et al.: Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur. J. Clin. Microbiol. Infect. Dis. (2001) 20(7):460-466.
89. DOKMETAS HS, CANBAY E, YILMAZ S et al.: Diabetic ketoacidosis and rhino-orbital mucormycosis. Diabetes Res. Clin. Pract. (2002) 57(2):139-142.
90. TSAOUSIS G, KOUTSOURI A, GATSIOU C, PANIARA O, PEPPAS C, CHALEVELAKIS G: Liver and brain mucormycosis in a diabetic patient type II successfully treated with liposomial amphotericin B. Scand. J. Infect. Dis. (2000) 32(3):335-337.
91. RICKERTS V, LOEFFLER J, BOHME A, EINSELE H, JUST-NUBLING G: Diagnosis of disseminated zygomycosis using a polymerase chain reaction assay. Eur. J. Clin. Microbiol. Infect. Dis. (2001) 20(10):744-745.
92. TROKE PF, ESPINEL-INGROFF A, JOHNSON EM, SCHLAMM H: Susceptibility of moulds from two open, randomized, comparative studies of the efficacy and safety of voriconazole (VORI) versus amphotericin B (AMB) in the treatment of acute invasive aspergillosis (AIA) in immunocompromised patients. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001) J-820.
93. PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. (2002) 46(4):1032-1037.
94. SUN QN, FOTHERGILL AW, MCCARTHY DI, RINALDI MG, GRAYBILL JR: In vitro activities of posaconazole, irraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. (2002) 46(5):1581-1582.
95. FAIRLEY C, SULLIVAN TJ, BARTLEY P, ALLWORTH T, LEWANDOWSKI R: Survival after rhino-orbital-cerebral mucormycosis in an immunocompetent patient. Ophthalmology (2000) 107(3):555-558.
96. HUNSTAD DA, COHEN AH, ST GEME JW 3rd: Successful eradication of mucormycosis occurring in a pulmonary allograft. J. Heart Lung Transplant (1999) 18(8):801-804.
97. DAS A, MACLAUGHLIN EF, ROSS LA et al.: Paecilomyces variotii in a pediatric patient with lung transplantation. Pediatr. Transplant (2000) 4(4):328-332.
98. HILMARSDOTTIR I, THORSTEINSSON SB, ASMUNDSSON P, BODVARSSON M, ARNADOTTIR M: Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scand. J. Infect. Dis. (2000) 32(3):331-332.
99. MARTINS CA, ROBERTS S, GREENBERG RN: Voriconazole treatment of disseminated Paecilomyces infection in a patient with acquired immune deficiency syndrome. Clin. Infect. Dis. (2002) 35:e78-e81.
100. WHEAT J, SAROSI G, MCKINSEY D et al.: Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):688-695.
101. WHEAT LJ, CONNOLLY P, HADDAD N, LE MONTE A, BRIZENDINE E, HAFNER R: Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrob. Agents Chemother. (2002) 46(1):248-250.
102. WHEAT LJ, CONNOLLY P, SMEDEMA M, BRIZENDINE E, HAFNER R: Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin. Infect. Dis. (2001) 33(11):1910-1913.
103. GRAYBILL JR, NAJVAR LK, MONTALBO EM, BARCHIESI FJ, LUTHER MF, RINALDI MG: Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob. Agents Chemother. (1998) 42(1):151-153.
104. KOHLER S, WHEAT LJ, CONNOLLY P et al.: Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. (2000) 44(7):1850-1854.
105. ESPINEL-INGROFF A: In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. (1998) 36(1):198-202.
106. CONNOLLY P, WHEAT J, SCHNIZLEIN-BICK C et al.: Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. (1999) 43(2):322-328.
107. CONNOLLY P, WHEAT LJ, SCHNIZLEIN-BICK C et al.: Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob. Agents Chemother. (2000) 44(10):2604-2608.
108. CLEMONS KV, LUTZ JE, STEVENS DA: Efficacy of interferon-γ and amphotericin B for the treatment of systemic murine histoplasmosis. Microbes Infect. (2001) 3(1):3-10.
109. DUONG TA: Infection due to Penicillium marneffei, in emerging pathogen: review of 155 reported cases. Clin. Infect. Dis. (1996) 23(1):125-130.
110. SAADIAH S, JEFFREY AH, MOHAMED AL: Penicillium marneffei infection in a non aids patient: first case report from Malaysia. Med. J. Malaysia (1999) 54(2):264-266.
111. SUPPARATPINYO K, PERRIENS J, NELSON KE, SIRISANTHANA T: A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N. Engl. J. Med. (1998) 339(24):1739-1743.
112. KAUFMAN L: Penicilliosis marneffei and pythiosis: emerging tropical diseases. Mycopathologia (1998) 143(1):3-7.
113. KAUFMAN L, STANDARD PG, JALBERT M, KANTIPONG P, LIMPAKARNJANARAT K, MASTRO TD: Diagnostic antigenemia tests for penicilliosis marneffei. J. Clin. Microbiol. (1996) 34(10):2503-2505.
114. RIMEK D, ZIMMERMANN T, HARTMANN M, PRARIYACHATIGUL C, KAPPE R: Disseminated Penicillium marneffei infection in an HIV-positive female from Thailand in Germany. Mycoses. (1999) 42(Suppl. 2):25-28.
115. IMWIDTHAYA P, THIPSUVAN K, CHAIPRASERT A, DANCHAIVIJITRA S, SUTTHENT R, JEARANAISILAVONG J: Penicillium marneffei: types and drug susceptibility. Mycopathologia (2001) 149(3):109-115.
116. RADFORD SA, JOHNSON EM, WARNOCK DW: In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. (1997) 41(4):841-843.
117. UCHIDA K, NISHIYAMA Y, YOKOTA N, YAMAGUCHI H: In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J. Antibiot. (2000) 53(10):1175-1181.
118. CHARIYALERTSAK S, SUPPARATPINYO K, SIRISANTHANA T, NELSON KE: A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin. Infect. Dis. (2002) 34(2):277-284.
119. LYRATSOPULOS G, ELLIS M, NERRINGER R, DENNING DW: Invasive infection due to penicillium species other than P. marneffei. J. Infect. (2002) 45(3):184-195.
120. GALGIANI JN, AMPEL NM, CATANZARO A, JOHNSON RH, STEVENS DA, WILLIAMS PL: Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):658-661.
121. GONZALEZ GM, TIJERINA R, NAJVAR LK et al.: Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob. Agents Chemother. (2001) 45(6):1854-1859.
122. LI RK, CIBLAK MA, NORDOFF N, PASARELL L, WARNOCK DW, MCGINNIS MR: In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. (2000) 44(6):1734-1736.
123. CHAPMAN SW, BRADSHER RW Jr, CAMPBELL GD Jr, PAPPAS PG, KAUFFMAN CA: Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):679-683.
124. PAPPAS PG, POTTAGE JC, POWDERLY WG et al.: Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. (1992) 116(10):847-853.
125. SUGAR AM, LIU XP: Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob. Agents Chemother. (2001) 45(2):601-604.
126. KAUFFMAN CA, HAJJEH R, CHAPMAN SW: Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):684-687.
127. MANNS BJ, BAYLIS BW, URBANSKI SJ, GIBB AP, RABIN HR: Paracoccidioidomycosis: case report and review. Clin. Infect. Dis. (1996) 23(5):1026-1032.
128. SKIKANAI-YASUDA MA, BEDARD G, HIGAKI Y et al.: Randomized trial with itraconazole, ketoconazole, and sulfadiazine in paracoccidioidomycosis. Med. Mycol. (2002) 40:411-417.
129. KAPPE R: Antifungal activity of the new azole UK-109, 496 (voriconazole). Mycoses (1999) 42(Suppl. 2):83-86.
130. MESA A, HENAO J, GIL M, DURANGO G: Phaeohyphomycosis in kidney transplant patients. Clin. Transplant. (1999) 13(3):273-276.
131. OHIRA S, ISODA K, HAMANAKA H, TAKAHASHI K, NISHIMOTO K, MIZUTANI H: Case report. Phaeohyphomycosis caused by Phialophora verrucosa developed in a patient with non-HIV acquired immunodeficiency syndrome. Mycoses (2002) 45(1-2):50-54.
132. NUCCI M, AKITI T, BARREIROS G et al.: Nosocomial outbreak of Exophiala jeanselmei fungemia associated with contamination of hospital water. Clin. Infect. Dis. (2002) 34(11):1475-1480.
133. OSIYEMI OO, DOWDY LM, MALLON SM, CLEARY T: Cerebral phaeohyphomycosis due to a novel species: report of a case and review of the literature. Transplantation (2001) 71(9):1343-1346.
134. CLANCY CJ, WINGARD JR, HONG NM: Subcutaneous phaeohyphomycosis in transplant recipients: review of the literature and demonstration of in vitro synergy between antifungal agents. Med. Mycol. (2000) 38(2):169-175.
135. MCGINNIS MR, PASARELL L: In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J. Clin. Microbiol. (1998) 36(8):2353-2355.
136. AL ABDELY HM, NAJVAR L, BOCANEGRA R et al.: SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ('Ramichloridium mackenziei'). Antimicrob. Agents Chemother. (2000) 44(5):1159-1162.
137. PATHAK A, PIEN FD, CARVALHO L: Amphotericin B use in a community hospital, with special emphasis on side effects. Clin. Infect. Dis. (1998) 26(2):334-338.
138. ANDERSON CM: Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care? West. J. Med. (1995) 162(4):313-317.
139. LLANOS A, CIEZA J, BERNARDO J et al.: Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int. (1991) 40(2):302-308.
140. WINGARD JR, WHITE MH, ANAISSIE E et al.: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. (2000) 31(5):1155-1163.
141. WINGARD JR: Lipid formulations of amphotericins: are you a lumper or a splitter? Clin. Infect. Dis. (2002) 35:891-895.
142. HOANG A: Caspofungin acetate: an antifungal agent. Am. J. Health-Syst. Pharm. (2001) 58(13):1206-1214.
143. HUSAIN S, SINGH N: The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin. Infect. Dis. (2002) 35(1):53-61.
144. WARRIS A, BJORNEKLETT A, GAUSTAD P: Invasive pulmonary aspergillosis associated with infliximab therapy. N. Engl. J. Med. (2001) 344(14):1099-1100.
145. LEE J, SLIFMAN NR, GERSHON SK et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum. (2002) 46(10):2564-2570.
146. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. (2001) 345(15):1098-1104.
147. SAAG MS, GRAYBILL RJ, LARSEN RA et al.: Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):710-718.
148. KONTOYIANNIS DP, LEWIS RE, SAGAR N, MAY G, PRINCE RA, ROLSTON KV: Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob. Agents Chemother. (2000) 44(10):2915-2918.
149. BAJJOKA IE, BAILEY EM, VAZQUEZ JA, ABOULJOUD MS: Combination antifungal therapy for invasive aspergillosis infection in liver transplant recipients: report of two patients. Pharmacotherapy (1999) 19(1):118-123.
150. LEWIS RE, LUND BC, KLEPSER ME, ERNST EJ, PFALLER MA: Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob. Agents Chemother. (1998) 42(6):1382-1386.
151. LOUIE A, KAW P, BANERJEE P, LIU W, CHEN G, MILLER MH: Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob. Agents Chemother. (2001) 45(2):485-494.
152. BARCHIESI F, SCHIMIZZI AM, CASELLI F et al.: Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44(9):2435-2441.
153. GEORGE D, KORDICK D, MINITER P, PATTERSON TF, ANDRIOLE VT: Combination therapy in experimental invasive aspergillosis. J. Infect. Dis. (1993) 168(3):692-698.
154. DENNING DW, STEVENS DA: Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. (1991) 35(7):1329-1333.
155. SUGAR AM, GOLDANI LZ, PICARD M: Treatment of murine invasive candidiasis with amphotericin B and cilofungin: evidence for enhanced activity with combination therapy. Antimicrob. Agents Chemother. (1991) 35(10):2128-2130.
156. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. (2002) 46(1):245-247.
157. KONTOYIANNIS DP, HACHEM R, LEWIS RE, RIVERO G, KANTARJIAN H, RAAD II: Efficacy and safety of the caspofungin/liposomal amphotericin B (CAS/LipoAMB) combination in possible or documented invasive aspergillosis (IA) in patients (Pts) in hematological malignancies. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002) M-1280.
158. KONTOYIANNIS DP, LEWIS RE, MAY GS, ALBERT ND, RAAD II: Sequential exposure of A. fumigatus to itraconazole (ITRA) and caspofungin (CAS): evidence of enhanced in vitro activity of this combination. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002) M-851.
159. GENTINA T, DE BOTTON S, ALFANDARI S, DELOMEZ J, JAILLARD S, LEROY O: Combination antifungals for treatment of pulmonary invasive aspergillosis (IS) refractory to amphotericin B (AmB) in leukaemia patients. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002) M-860.
160. CAGNONI PJ, WALSH TJ, PRENDERGAST MM et al.: Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. (2000) 18(12):2476-2483.
161. KUTI JL, KOTAPATI S, WILLIAMS P, CAPITANO B, NIGHTINGALE CH, NICOLAU DP: Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002) O-1000.
162. APOTHECON: Fungizone (amphotericin B deoxycholate) package insert. Princeton, NJ 1993. (2002).
163. Drug Topics Red Book. Medical Economics Company, Montvale, NJ (2002).